Calculate isotretinoin cumulative dose, track treatment progress, and review lab values. Includes dosing by severity, iPLEDGE reminders, and lab schedules.
The Isotretinoin (Accutane) Dose Calculator helps track cumulative dosing, estimate treatment duration, and monitor safety values during isotretinoin therapy. The key clinical idea is the cumulative dose target, which is usually expressed in mg/kg and used to guide how long treatment should continue.
This calculator computes the target cumulative dose from body weight, compares that target with the dose already taken, estimates the remaining treatment time at the current daily dose, and shows common dose ranges by acne severity.
It also supports lab-review context by flagging ALT and triglyceride elevations, along with reminders about common iPLEDGE-style workflow categories and follow-up timing.
Isotretinoin treatment is usually managed around a cumulative-dose target, so it helps to see the current dose, the target, and the remaining treatment time together. That makes it easier to follow progress without doing the arithmetic by hand.
Target Cumulative Dose (mg) = Target (mg/kg) × Weight (kg). Dose per kg/day = Daily dose (mg) / Weight (kg). Cumulative dose = Daily dose × Days completed. Days remaining = Remaining dose / Daily dose. Standard target: 120-150 mg/kg total cumulative dose.
Result: 2,400 mg completed (34.3 mg/kg) of 8,400 mg target — 150 days remaining
At 40 mg/day for 60 days, cumulative dose is 2,400 mg (34.3 mg/kg). Target is 120 mg/kg × 70 kg = 8,400 mg. Remaining: 6,000 mg ÷ 40 mg/day = 150 more days (~5 months). Total course: ~7 months.
Isotretinoin's mechanism involves normalizing keratinocyte differentiation, dramatically reducing sebum production (by up to 90%), reducing Cutibacterium acnes colonization, and decreasing inflammation. The cumulative dose concept emerged from observations that relapse rates correlate inversely with total drug exposure. Strauss et al. established the 120 mg/kg guideline, but subsequent studies have shown continued benefit at higher cumulative doses.
The 120 mg/kg target represents the point where approximately 80% of patients achieve durable remission. Raising the target to 150 mg/kg improves this to approximately 85-90%. Some aggressive protocols targeting 220 mg/kg report relapse rates under 5%, though with increased side effect burden. The optimal target likely depends on individual factors including acne severity, sebum production, and response to treatment.
Almost all patients experience mucocutaneous dryness — cheilitis (dry lips) in virtually 100%, dry skin in 50-80%, and dry eyes in 20-30%. These effects are dose-dependent and usually reversible. Moisturizers, lip care, artificial tears, and dose adjustments are common parts of follow-up discussions.
Musculoskeletal symptoms (arthralgias, myalgias, back pain) affect 15-30% of patients. Follow-up blood work is commonly reviewed early in the course, and the schedule may change later if values remain stable.
Isotretinoin is a known teratogen and is contraindicated in pregnancy because fetal exposure can cause severe birth defects, miscarriage, stillbirth, and premature birth. The iPLEDGE REMS program was implemented in 2006 to prevent fetal exposure and includes monthly pregnancy-testing and contraception workflow requirements for patients who can become pregnant, along with coordination between patients, prescribers, and pharmacies through a centralized online system.
Last updated:
This worksheet multiplies body weight by the selected cumulative-dose target, compares that target with the dose already taken, and converts the remaining milligrams into estimated remaining days at the current daily dose. It is a treatment-planning aid, not a dosing order or a safety protocol.
The traditional target of 120 mg/kg comes from early studies by Strauss et al. More recent data (Blasiak 2013, Coloe 2011) suggest that 150 mg/kg and higher may reduce relapse rates from 20-30% to 10-15%. Some dermatologists now target 150-220 mg/kg for severe acne.
Yes — isotretinoin absorption nearly doubles when taken with a fatty meal (≥20g fat). Always take it with food to maximize bioavailability and reach your cumulative target more efficiently. Fasted absorption can be as low as 50% of fed absorption.
Most courses run 5-7 months at standard dosing (0.5-1.0 mg/kg/day). Treatment duration depends on the target cumulative dose divided by the daily dose. Lower daily doses extend the course but may have fewer side effects.
iPLEDGE is a mandatory REMS program for isotretinoin prescribing in the US. The exact workflow depends on patient category, and the pregnancy-testing requirements apply specifically to patients who can become pregnant. This calculator only summarizes that context; it does not replace the actual program steps.
Larger ALT or triglyceride elevations usually prompt prescribing-clinician review, especially when values are clearly above baseline or continue to rise. This calculator shows broad reference ranges only; actual response depends on fasting status, symptoms, baseline labs, and the treating clinician's plan.
Low-dose protocols (10-20 mg/day or 0.15-0.4 mg/kg/day) are increasingly used for moderate acne and adult acne. They have fewer side effects but require longer treatment (12-18 months) to reach the same cumulative target. Efficacy appears comparable in some studies.